Teva Pharmaceutical Industries (NYSE: TEVA) is an interesting investment story. For the right investor, it could be an attractive buy. For me, however, it isn't. Here's the opportunity that Teva has ...

Amneal Pharmaceuticals (NASDAQ:AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy healthcare stocks to invest in.

Allspring SMID Cap Growth Fund reports on Q4 market rotations and performance drivers like Teva and Natera. Read the full ...

Allspring SMID Cap Growth Fund reviews Q4 2025 performance and identifies high-quality growth opportunities. Read the full ...

Eleven community-based organizations were selected as the first recipients of Baltimore City's Opioid Restitution Fund community grants.

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

He explains why expressing the hard stuff matters: "It made me realize how important communication and support are." ...

U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) said on Friday that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release ...

Corcept Therapeutics lost its patent-infringement battle with Teva Pharmaceutical Industries, exposing Corcept to more competition from generic drugs. The ruling from the U.S. Court of Appeals for the ...

Teva Pharmaceutical Indus (NYSE: TEVA) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of ...

Greenlight Capital's David Einhorn has been vocal about his concerns around artificial intelligence driving overvaluation in ...